Form 4: Director Acquires Shares Post-Hyperliquid Merger

Hyperliquid Strategies Inc. director Nailesh Bhatt acquired 2,082 shares of common stock following the completion of a business combination with Sonnet BioTherapeutics Holdings, Inc.

Summary

• Nailesh Bhatt, a Director of Hyperliquid Strategies Inc., acquired 2,082 shares of the company's common stock.
• The acquisition occurred on December 2, 2025, in connection with the closing of a previously announced business combination.
• The business combination involved Hyperliquid Strategies Inc., Sonnet BioTherapeutics Holdings, Inc., Rorschach I LLC, TBS Merger Sub Inc., and Rorschach Merger Sub, LLC.
• Ms. Bhatt received these shares in exchange for certain securities of Sonnet BioTherapeutics Holdings, Inc. that she held prior to the closing.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The filing reports the expected completion of a business combination and a director's acquisition of shares as part of that process, which is generally a neutral to positive event indicating strategic execution and insider confidence.

Positives

• A director acquiring shares can be interpreted as a positive signal of confidence in the combined entity's future prospects.
• The completion of the business combination indicates successful execution of a strategic corporate initiative.

Future Outlook

The filing indicates the successful completion of a strategic business combination, which may lead to future operational and financial integration efforts for the combined entity.

Industry Context

This transaction reflects the ongoing consolidation and strategic realignments common in various industries, where companies merge to achieve synergies, expand market reach, or integrate technologies. The exchange of securities suggests a non-cash transaction typical in such business combinations.

Stakeholder Impact

• Shareholders: The completion of the business combination could impact the strategic direction and future value of their holdings. A director's share acquisition may signal confidence.
• Employees: Integration of the two companies may lead to organizational changes.

Next Steps

• Integration of Hyperliquid Strategies Inc. and Sonnet BioTherapeutics Holdings, Inc. following the business combination.

Key Dates

Keywords

Hyperliquid Strategies Inc, PURR, Nailesh Bhatt, Director, Share Acquisition, Business Combination, Merger, Sonnet BioTherapeutics Holdings Inc, SEC Form 4, Insider Trading, Beneficial Ownership